TWI887191B - 合成之嵌合痘病毒 - Google Patents

合成之嵌合痘病毒 Download PDF

Info

Publication number
TWI887191B
TWI887191B TW106137976A TW106137976A TWI887191B TW I887191 B TWI887191 B TW I887191B TW 106137976 A TW106137976 A TW 106137976A TW 106137976 A TW106137976 A TW 106137976A TW I887191 B TWI887191 B TW I887191B
Authority
TW
Taiwan
Prior art keywords
virus
vacv
scopv
genome
cells
Prior art date
Application number
TW106137976A
Other languages
English (en)
Chinese (zh)
Other versions
TW201819400A (zh
Inventor
大衛 伊凡斯
芮恩 諾伊斯
賽斯 雷德曼
Original Assignee
大衛 伊凡斯
芮恩 諾伊斯
賽斯 雷德曼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大衛 伊凡斯, 芮恩 諾伊斯, 賽斯 雷德曼 filed Critical 大衛 伊凡斯
Publication of TW201819400A publication Critical patent/TW201819400A/zh
Application granted granted Critical
Publication of TWI887191B publication Critical patent/TWI887191B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW106137976A 2016-11-02 2017-11-02 合成之嵌合痘病毒 TWI887191B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US62/416,577 2016-11-02
US201662434794P 2016-12-15 2016-12-15
US62/434,794 2016-12-15

Publications (2)

Publication Number Publication Date
TW201819400A TW201819400A (zh) 2018-06-01
TWI887191B true TWI887191B (zh) 2025-06-21

Family

ID=62075555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106137976A TWI887191B (zh) 2016-11-02 2017-11-02 合成之嵌合痘病毒
TW113144133A TW202528334A (zh) 2016-11-02 2017-11-02 合成之嵌合痘病毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113144133A TW202528334A (zh) 2016-11-02 2017-11-02 合成之嵌合痘病毒

Country Status (14)

Country Link
US (2) US11345896B2 (enExample)
EP (1) EP3535389A4 (enExample)
JP (3) JP2019535311A (enExample)
CN (1) CN110431228B (enExample)
AU (2) AU2017353868C1 (enExample)
BR (1) BR112019008781A2 (enExample)
CA (1) CA3042694A1 (enExample)
IL (2) IL319942A (enExample)
MX (1) MX2019005102A (enExample)
NZ (1) NZ752893A (enExample)
SG (1) SG11201903893PA (enExample)
TW (2) TWI887191B (enExample)
WO (1) WO2018085582A1 (enExample)
ZA (3) ZA201902868B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
WO2018148710A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
JP2021522784A (ja) * 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
WO2021174142A1 (en) 2020-02-26 2021-09-02 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against sars-cov-2 virus
MX2023009008A (es) 2021-02-02 2023-10-05 Geovax Inc Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación.
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CN105121635B (zh) 2013-04-10 2018-10-16 东源生物医药科技（上海）有限公司 突变型痘苗病毒株、其用途及其制造方法
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ． ソーン， 高移動度グループｂｏｘｉ突然変異体
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
TW202014200A (zh) 2018-05-02 2020-04-16 賽斯 雷德曼 包含合成嵌合牛痘病毒之幹細胞及其使用方法
JP2021522784A (ja) 2018-05-02 2021-09-02 トニックス ファーマ ホールディングス リミテッド 合成キメラワクシニアウイルス

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Xiao-Dan Yao et al., Construction of Recombinant Vaccinia Viruses Using Leporipoxvirus-Catalyzed Recombination and Reactivation of Orthopoxvirus DNA. Methods in Molecular Biology. 269: doi: 10.1385/1-59259-789-0:051. 2004; 51-64. *
期刊 Xiao-Dan Yao et al., High-Frequency Genetic Recombination and Reactivation of Orthopoxviruses from DNA Fragments Transfected into Leporipoxvirus-Infected Cells. Journal of Virology. 77(13): doi: 10.1128/jvi.77.13. 2003 Jul; 7281-7290.; *

Also Published As

Publication number Publication date
US12365879B2 (en) 2025-07-22
EP3535389A4 (en) 2020-06-03
IL319942A (en) 2025-05-01
CN110431228A (zh) 2019-11-08
AU2017353868B2 (en) 2024-02-29
WO2018085582A1 (en) 2018-05-11
AU2017353868C1 (en) 2024-06-06
NZ752893A (en) 2025-10-31
ZA201902868B (en) 2022-12-21
CA3042694A1 (en) 2018-05-11
SG11201903893PA (en) 2019-05-30
IL266399B2 (en) 2025-09-01
ZA202403393B (en) 2025-08-27
EP3535389A1 (en) 2019-09-11
US20180251736A1 (en) 2018-09-06
IL266399B1 (en) 2025-05-01
AU2017353868A1 (en) 2019-05-16
JP2019535311A (ja) 2019-12-12
AU2024200997A1 (en) 2024-03-07
JP2024107257A (ja) 2024-08-08
JP2022164900A (ja) 2022-10-27
CN110431228B (zh) 2024-04-02
MX2019005102A (es) 2019-10-30
US20230002741A1 (en) 2023-01-05
ZA202204981B (en) 2024-09-25
TW202528334A (zh) 2025-07-16
TW201819400A (zh) 2018-06-01
BR112019008781A2 (pt) 2019-07-16
US11345896B2 (en) 2022-05-31
IL266399A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
TWI887191B (zh) 合成之嵌合痘病毒
JP2025178289A (ja) 合成キメラワクシニアウイルス
AU2021226592A1 (en) Recombinant poxvirus based vaccine against SARS-CoV-2 virus
CA2372709C (en) Vector for integration of heterologous sequences into poxviral genomes
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40014109B (zh) 合成嵌合痘病毒
HK40014109A (en) Synthetic chimeric poxviruses
Ourahmane et al. A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus
Hu The development of penguinpox virus (PEPV) as a vaccine vector: transfer vector construction and rescue of virus growth in rabbit kidney cells (RK-13) by vaccinia virus K1
Ríos et al. INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.